Scott Antonia, M.D., Ph.D.
Scott Antonia, M.D., Ph.D. is recognised as a global leader in the development of immunotherapy for lung cancer. He currently serves as the director of the Duke Cancer Institute (DCI) Center for Cancer Immunotherapy and is a member of the Thoracic Oncology disease group as Professor of Medical Oncology. He previously served as the chairman of the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center. He has served as the global principal investigator for the practice-changing Pacific study, which established, as the new global standard of care, anti-PDL1 as consolidative therapy after combined chemo-radiation therapy for locally advanced non-small cell lung cancer. He was also the lead investigator of trials that established the clinical activity of immunotherapy for small cell lung cancer. For the past 27 years, Professor Antonia has directed a translational research program with the overall goal to develop immunotherapeutic strategies for the treatment of cancer patients.